What happened

Shares of The Medicines Company (NASDAQ:MDCO), a biopharmaceutical company focused on lowering cholesterol, are on the move again following yesterday's presentation of the Orion-11 trial results. Healthcare-minded investors pleased with the details drove the stock 10.4% higher on Tuesday.

So what

Last week, The Medicines Company stock jumped after the company announced positive results from Orion-11, the first of three pivotal studies with inclisiran that the company will present before the end of 2019. The Medicines Company kept a lid on the details until yesterday's presentation at the European Society of Cardiology's annual meeting, and investors are happy with what they saw.

Money raining down on a happy person.

Image source: Getty Images.

Inclisiran is a twice-yearly injection for people with stubbornly high levels of low-density lipoprotein cholesterol (LDL-C). The Orion-11 study was looking for a significant improvement to patients' LDL-C scores, and it succeeded on this front. At the 510-day observation, inclisiran delivered placebo-adjusted LDL-C reductions of 54% without any serious side effects.

Now what

Later this year, The Medicines Company will present results from Orion-9, a study with heterozygous familial hypercholesterolemia patients. This group is frequently injected with PCSK9 inhibitors, such as Repatha from Amgen (NASDAQ:AMGN), every other week.

We'll also see results from Orion-10, and they'll probably look a lot like Orion-11 results. The Orion-11 trial enrolled people throughout Europe with atherosclerotic cardiovascular disease (ASCVD) or equivalent risk factors. Orion-10 is essentially the U.S. version of Orion-11, with one slight difference: Orion-10 is full of patients with ASCVD.

It's still a little early, but investors can probably look forward to more positive results this year and a new drug application in 2020. Peak annual sales of inclisiran are expected to top $2 billion, and signs The Medicines Company can make it happen could drive the stock much higher down the line.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.